This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Arena Trading Surges Ahead of Key FDA Drug Approval Decision

Stocks in this article: ARNA VVUS

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Updated with stock price.

SAN DIEGO ( TheStreet) -- Arena Pharmaceuticals' (ARNA) share price and trading volume are sharply higher two weeks in front of an expected U.S. approval decision on the company's weight-loss drug.

With 30 minutes remaining in Wednesday's regular trading session, almost 54 million shares of Arena have already traded hands with the stock up 1.5% to $8.00 -- near a five-year high. Average daily volume in the stock is 16 million shares.

This frenzied trading in Arena looks to have started last Friday and has accelerated over the past three trading days. On Tuesday, Arena shares rose 11% on volume of almost 38 million shares.

"Everyone is scratching their heads," said one institutional investor who follows biotech stocks closely.

The U.S. Food and Drug Administration is expected to issue an approval decision on June 27 for Arena's weight-loss drug lorcaserin. An FDA advisory panel held May 10 voted to recommend lorcaserin's approval.

Trying to nail down the exact reasons for the sudden spike in Arena trading is difficult. Arena CEO Jack Lief met with Wall Street investors at a healthcare investor conference last week, where he expressed optimism about an on-time FDA approval without a risk-management plan for lorcaserin, according to two investors who met privately with Lief.

Some investors and analysts have speculated that FDA could delay lorcaserin's approval by three months to give the agency more time to review the drug and finalize a risk-management plan to ensure safe use.

"I don't think institutions are piling into Arena but it's possible. Honestly, I don't know what's going on with the stock," said one of the investors who met with Lief.

Institutional ownership of Arena has been relatively low given widespread skepticism about lorcaserin's modest ability to shed weight. But mutual funds and other large Wall Street investors may be new converts and upping their ownership in Arena following the positive FDA panel and belief that FDA will follow through with a full approval.

Arena's short position was almost 40 million shares as of May 31, which could also help explain the stock's recent movement.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs